Company to conduct 1x1 meetings on April 24, 2025
DENVER, CO / ACCESS Newswire / April 21, 2025 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced that it will be presenting at the Planet MicroCap Showcase: VEGAS 2025 in partnership with MicroCapClub on Wednesday, April 23, 2025, at 1:30 p.m. Pacific time (4:30 p.m. Eastern time). Josh Disbrow, CEO of Aytu, will be hosting the presentation and answering questions at the conclusion.
Planet MicroCap Showcase: VEGAS 2025 in partnership with MicroCapClub
Date: Wednesday, April 23, 2025
Time: 1:30 p.m. Pacific time (4:30 p.m. Eastern time)
Location: Track 3 - Chablis at the Paris Hotel & Casino in Las Vegas, NV
Webcast: https://event.summitcast.com/view/YNz6mnmEsXyrdRxb78w2nX/TAxDfjTKnVPjtQrR4ybMca
If you would like to schedule a 1x1 meeting with management, please contact your Planet MicroCap representative or the Company's investor relations team at 1x1@lythampartners.com. 1x1 meetings will be scheduled and conducted in person on April 24, 2025, at the conference venue: Paris Hotel & Casino in Las Vegas, NV
About Aytu BioPharma, Inc.
Aytu is a pharmaceutical company focused on commercializing novel therapeutics. The Company's prescription products include Adzenys XR-ODT® (amphetamine) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) and Cotempla XR-ODT® (methylphenidate) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) for the treatment of attention deficit hyperactivity disorder (ADHD), Karbinal® ER (carbinoxamine maleate), an extended-release antihistamine suspension indicated to treat numerous allergic conditions, and Poly-Vi-Flor® and Tri-Vi-Flor®, two complementary fluoride-based prescription vitamin product lines available in various formulations for infants and children with fluoride deficiency. To learn more, please visit aytubio.com.
Contacts for Investors
Ryan Selhorn, Chief Financial Officer
Aytu BioPharma, Inc.
rselhorn@aytubio.com
Robert Blum or Roger Weiss
Lytham Partners
aytu@lythampartners.com
SOURCE: Aytu BioPharma, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。